A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic

International Journal of Antimicrobial Agents

Volumn 33, Issue 1, 2009, Pages 58-64

  File Jr , Thomas M ^a,b   Monte, Scott V ^c,d   Schentag, Jerome J ^c,d   Paladino, Joseph A ^c,d   Klugman, Keith P ^e   Lavin, Bruce ^f   Yu, Victor L ^g   Singer, Mendel E ^h   Adelman, Martin H ^c,d  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d CPL Associates LLC   (United States)

^e EMORY UNIVERSITY   (United States)

^f Ringoes   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

CAP; COPD; GOLD like group (GLG); Progression models; S. pneumoniae

Indexed keywords

CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CLEARANCE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BRONCHITIS, CHRONIC; COMMUNITY-ACQUIRED INFECTIONS; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG; LUNG DISEASES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; STREPTOCOCCUS PNEUMONIAE;

EID: 59349104361     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.07.019     Document Type: Article

References (17)

1. Bouza E., Pintado V., Rivera S., Blazquez R., Munoz P., Cercenado E., et al. Nosocomial bloodstream infections caused by Streptococcus pneumoniae. Clin Microbiol Infect 11 (2005) 919-924
2. Arancibia F., Bauer T., Ewig S., Mensa J., Gonzalez J., Niederman M., et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 162 (2002) 1849-1858
3. Aspa J., Rajas O., Rodriguez de Castro F., Blanquer J., Zalacain R., Renoll A., et al., Pneumococcal Pneumonia in Spain Study Group. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 38 (2004) 787-798
4. Goss C.H., Rubenfeld G.D., Park D.R., Sherbin V.L., Goodman M.S., and Root R.K. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. Chest 124 (2003) 2148-2155
5. Lonks J., Garau J., Gomez L., Xervavins M., Ochoa de Echaquen A., Gareen I.F., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35 (2002) 556-564
6. Menendez R., Torres A., Zalacain R., Aspa J., Martin Villasclaras J., Borderias L., et al., Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 59 (2004) 960-965
7. Torres A., Dorca J., Zalacain R., Bello S., El-Ebiary M., Molinos L., et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 154 (1996) 1456-1461
8. Chen D.K., McGeer A., de Azevedo J.C., and Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 341 (1999) 233-239
9. Ball P., Harris J.M., Lowson D., Tillotson G., and Wilson R. Acute infective exacerbations of chronic bronchitis. QJM 88 (1995) 61-68
10. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. http://www.goldcopd.org [accessed 5 October 2007].
11. Pauwels R., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S., and GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163 (2001) 1256-1276
12. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., and Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987) 196-204
13. Amsden G.W., Ballow C.H., and Schentag J.J. Population pharmacokinetic methods to optimise antibiotic effects. Drug Invest 5 (1993) 256-268
14. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
15. Schentag J.J., Klugman K.P., Yu V.L., Adelman M.H., Wilton J.H., Chiou C.C., et al. Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance-a controlled study. Int J Antimicrob Agents 30 (2007) 264-269
16. Schentag J.J., Nix D.E., and Adelman M.H. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP 25 (1991) 1050-1057
17. Daneman N., McGeer A., Green K., Low D.E., and Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 43 (2006) 432-438